183 related articles for article (PubMed ID: 26294726)
21. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
22. A mathematical model of cell equilibrium and joint cell formation in multiple myeloma.
Koenders MA; Saso R
J Theor Biol; 2016 Feb; 390():73-9. PubMed ID: 26643942
[TBL] [Abstract][Full Text] [Related]
23. Chemokines in multiple myeloma.
Aggarwal R; Ghobrial IM; Roodman GD
Exp Hematol; 2006 Oct; 34(10):1289-95. PubMed ID: 16982321
[TBL] [Abstract][Full Text] [Related]
24. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
25. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.
Bi Y; Nielsen KL; Kilts TM; Yoon A; A Karsdal M; Wimer HF; Greenfield EM; Heegaard AM; Young MF
Bone; 2006 Jun; 38(6):778-86. PubMed ID: 16364709
[TBL] [Abstract][Full Text] [Related]
26. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation.
Bennett CN; Ouyang H; Ma YL; Zeng Q; Gerin I; Sousa KM; Lane TF; Krishnan V; Hankenson KD; MacDougald OA
J Bone Miner Res; 2007 Dec; 22(12):1924-32. PubMed ID: 17708715
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
28. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.
Tanno T; Lim Y; Wang Q; Chesi M; Bergsagel PL; Matthews G; Johnstone RW; Ghosh N; Borrello I; Huff CA; Matsui W
Blood; 2014 Jan; 123(5):725-33. PubMed ID: 24345755
[TBL] [Abstract][Full Text] [Related]
29. CGRP may regulate bone metabolism through stimulating osteoblast differentiation and inhibiting osteoclast formation.
He H; Chai J; Zhang S; Ding L; Yan P; Du W; Yang Z
Mol Med Rep; 2016 May; 13(5):3977-84. PubMed ID: 27035229
[TBL] [Abstract][Full Text] [Related]
30. The multiple myeloma bone eco-system and its relation to oncogenesis.
Bataille R
Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
[TBL] [Abstract][Full Text] [Related]
31. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
32. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both?
Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F
Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760
[TBL] [Abstract][Full Text] [Related]
33. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
[TBL] [Abstract][Full Text] [Related]
34. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA
Blood Cancer J; 2018 Jan; 8(1):7. PubMed ID: 29330358
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
37. [Research on mechanism underlying bone damage in myeloma--review].
Zhou LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1340-4. PubMed ID: 18088497
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
39. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades.
Qu X; Zhai Z; Liu X; Li H; Ouyang Z; Wu C; Liu G; Fan Q; Tang T; Qin A; Dai K
Biochem Biophys Res Commun; 2014 Jan; 443(2):658-65. PubMed ID: 24333429
[TBL] [Abstract][Full Text] [Related]
40. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
Abe M
Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
